IN-TIME Study Shows Significant Reduction in All-Cause Mortality in ICD and CRT-D Patients With BIOTRONIK Home Monitoring(R)September 1, 2013 5:09 am | by The Associated Press | News | Comments
BIOTRONIK, the leading manufacturer of cardiac devices celebrating its 50th anniversary this year, announced ground-breaking results from the IN-TIME study today at the ESC (European Society of Cardiology) congress. Coordinating investigator of IN-TIME, Professor Gerhard...
A sales rep's visit could be worth as much as $230 per case in surgeons' use of coronary stents, according to a study in the American Heart Journal. The presence of a company sales rep in the cath lab increased the likelihood that surgeons would opt for drug-eluting over bare-metal stents, researchers said.
When a beating heart slips into an irregular, life-threatening rhythm, the treatment is well known: deliver a burst of electric current from a pacemaker or defibrillator. But because the electricity itself can cause pain, tissue damage and other serious side-effects, a Johns Hopkins-led research team wants to replace these jolts with a kinder, gentler remedy: light.
St. Jude Medical, Inc., a global medical device company, today announced the CE Mark approval of its next-generation EnligHTN Renal Denervation System for treating patients with drug-resistant, uncontrolled hypertension. The system features an advanced generator that delivers simultaneous ablations via a multi-electrode catheter...
The National Institutes of Health (NIH) has awarded a five-year, $1.94 million grant to a biomedical research team at Worcester Polytechnic Institute (WPI) working at the forefront of cell therapies for healing cardiac muscle damaged by heart attack or chronic disease.
CardioKinetix Announces First Heart Failure Patients Treated in Asia with Minimally Invasive Structural Heart DeviceAugust 29, 2013 8:00 am | by Business Wire | News | Comments
CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced a new first with four patients successfully treated this week with the novel catheter-based Parachute ® Ventricular Partitioning Device in Kuala Lumpur, Malaysia.
Within the medical device technology industry, the cardiovascular sector is one of the largest and most stable, due to immediate demand and necessity. As with all areas in the field, engineers continuously strive to design more minimally invasive devices, but with cardiovascular diseases at the top of the list in a growing elderly population, there is an urgent need for continuous advancement.
Cordis Corp., the stent-making arm of Johnson & Johnson, got out of the coronary stent game 2 years go, but that's not stopping Israeli medical device company Medinol from suing Cordis for patent infringement with the Cypher and Cypher Select stents it no longer makes.
Medical device giant Medtronic is handing its Pioneer Plus re-entry catheter product line over to Volcano for an undisclosed amount, the companies announced this week. The deal, which Volcano hopes will help it expand its reach in peripheral indications, is expected to close this month and is structured as an "asset purchase."
Lombard Medical Technologies PLC, the specialist medical technology company focused on innovative vascular products, today announces that the first U.S. patients have been successfully treated with Aorfix, the Group’s flexible stent graft for the endovascular repair of abdominal aortic aneurysms.
Hansen Medical enrolled the 1st 5 patients in a re-designed study to evaluate its robot-assisted atrial fibrillation treatment. The revised study design, which won conditional FDA approval in May, will eventually enroll 125 patients at 14 medical centers to test Hansen's Sensei X robotic catheter system with the company's Artisan control catheters.
HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an IDE Supplement that allows HeartWare to commence enrollment in an additional patient cohort for ENDURANCE...
Massachusetts-based Abiomed (NSDQ:ABMD) won a lucrative 5-year contract to provide its flagship Impella heart pumps to the Veterans Administration, a deal that could boost the medical device maker's revenue by 20%. Abiomed can provide Impella to about 170 VA medical facilities, more than 40 Defense Dept. hospitals and other federal agencies via an automated online system, according to a company statement.
Volcano Corporation Announces Execution Of Agreement To Purchase Pioneer PlusT Re-Entry Catheter Product Line From MedtronicAugust 26, 2013 4:05 pm | by The Associated Press | News | Comments
Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today it has signed an agreement to acquire the Pioneer PlusT diagnostic ultrasound ...
Starting today, medical device giant Medtronic is banned from selling its CoreValve and CoreValve Evolut transcatheter aortic valve implantation systems in Germany, thanks to a court ruling in favor of rival device maker Edwards Lifesciences.
Irvine, Calif. medical device maker Reverse Medical Corp. touted FDA clearance for its flagship product, the MVP micro vascular plug for peripheral artery embolization. The plug helps decrease blood flow in the peripheral vasculature and is "completely re-sheathable" for use in procedures where a patient needs only temporary blood flow reduction.
In a scientific first, Harvard Stem Cell Institute scientists have successfully grown the cells that line the blood vessels—called vascular endothelial cells—from human induced pluripotent stem cells (iPSCs), revealing new details about how these cells function.
Researchers have developed a new technique that might one day be used to convert cells from heart disease patients into heart muscle cells that could act as a personalized treatment for their condition.
Researchers in India have carried out a data mining exercise to determine which are the most important risk factors in increasing the chances of an individual suffering a heart attack. The use of computational data mining techniques that allow researchers to extract interesting and meaningful information from real-life clinical data could remove at least some aspect of the subjectivity of clinical prognosis.
Boston Scientific Corporation continues to expand its electrophysiology (EP) offerings with U.S. Food and Drug Administration (FDA) approval of its IntellaTip MiFi™ XP catheter and 510(k) clearance of its Zurpaz™ 8.5F steerable sheath.
The Japanese Market For Peripheral Vascular Devices Will Be Characterized By New Product Launches In Many SegmentsAugust 22, 2013 8:00 am | by PR Newswire | News | Comments
According to Millennium Research Group, the global authority on medical technology market intelligence, efforts to streamline the regulatory approval process in Japan have resulted in the recent entry of numerous devices in the Japanese peripheral vascular (PV) device market, and more products, such as drug-coated balloons and infrapopliteal stents, are expected to enter in the next few years.
Boston Scientific Completes Enrollment In SuperNOVA Trial Evaluating Innova™ Self-Expanding Stent SystemAugust 19, 2013 6:02 pm | by PR Newswire | News | Comments
Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the SuperNOVA trial – a global, single arm, prospective, multicenter trial evaluating the long-term (12 month) safety and effectiveness of the Innova™ Self-Expanding Stent System (Innova Stent System).
AngioDynamics Applauds National Institute for Health and Care Excellence's (NICE) Updated Guidelines for Varicose Vein TreatmentAugust 19, 2013 4:45 pm | by Globe Newswire | News | Comments
AngioDynamics, a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, applauds the decision by National Institute for Health and Care Excellence (NICE) to issue updated guidance for the treatment of varicose veins.
ROX Medical has crossed the halfway point in the CONTROL-HTN international, multi centre, randomized controlled hypertension trial. The milestone was met with the enrollment of the first patient from Prof. Markus van der Giet and Prof. Walter Zidek of the Charite Hospital, Benjamin Franklin Campus, Berlin.
JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, announced today that it has successfully completed the first two implantations of its second-generation transapical JenaValve TAVI system in Canada.